Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ahad Sadiq"'
Autor:
Michael McCleod, Alona Zer, Steven L. McCune, Marcin Kowanetz, Henry Jacob Conter, Hans-Georg Kopp, Tarek Mekhail, Niels Reinmuth, W. Lin, Ahad Sadiq, Lijia Wang, Alan Sandler, Maen A. Hussein, Federico Cappuzzo, V. Archer, Achim Rittmeyer, Davey B. Daniel, Howard Jack West, Tania Ochi Lohmann, Alessandro Morabito
Publikováno v:
The Lancet Oncology. 20:924-937
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with ch
Autor:
Bradford A. Tan, Patrick Ward, Jeff Edenfield, Alexa B. Schrock, Dean Pavlick, Jeffrey P. Gregg, Gerald Li, Brady Forcier, Ahad Sadiq, Julio Peguero, Todd M. Bauer, Andre Kallab, Michelle Nahas, Siraj M. Ali, Matthew Cooke, Jeffrey S. Ross, Jie He, Jason D. Hughes, Anthony Hoffman, Jon Chung, Phil Stephens, Jose A. Bufill, Vincent A. Miller
Publikováno v:
Journal of gastrointestinal oncology. 10(5)
Background: Liquid biopsy offers the ability to non-invasively analyze the genome of a tumor through circulating tumor DNA (ctDNA) to identify targetable and prognostic genomic alterations. Few studies have rigorously analyzed ctDNA results and deter
Autor:
Smita S, Joshi, Daniel V T, Catenacci, Theodore G, Karrison, Jaclyn D, Peterson, Mark M, Zalupski, Amikar, Sehdev, James, Wade, Ahad, Sadiq, Vincent J, Picozzi, Andrea, Amico, Robert, Marsh, Mark F, Kozloff, Blase N, Polite, Hedy L, Kindler, Manish R, Sharma
Publikováno v:
Clin Cancer Res
PURPOSE: 5-fluorouracil/leucovorin, irinotecan, and nab-paclitaxel are all active agents in gastrointestinal cancers; the combination, FOLFIRABRAX, has not been previously evaluated. UDP Glucuronosyltransferase 1A1 (UGT1A1) clears SN-38, the active m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cabdc7547742e2d5fe3dd8861c6b7c71
https://europepmc.org/articles/PMC6942629/
https://europepmc.org/articles/PMC6942629/
Autor:
Niels Reinmuth, Lijia Wang, Alessandro Morabito, Steven L. McCune, Marcin Kowanetz, Ahad Sadiq, Helen Jessop, Hans-Georg Kopp, Michael McCleod, Tania Ochi Lohmann, Alan Sandler, Alona Zer, Davey B. Daniel, Tarek Mekhail, Maen A. Hussein, V. Archer, Achim Rittmeyer, Henry Jacob Conter, Federico Cappuzzo, Howard West
Publikováno v:
Cancer Research. 79:CT200-CT200
Background: Atezolizumab (atezo) (anti-PD-L1) monotherapy improves overall survival (OS) vs docetaxel in 2L+ NSCLC regardless of PD-L1 status; phase 3, 1L studies have shown clinical benefit of atezo plus chemotherapy and atezo in combination with be